Global orthopedic sales totaled $62 billion in 2024, an increase of 5% compared to 2023. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
The Numbers
A look at the current state of the foot and ankle market, the growth of core trauma and ways that smaller players are leveraging niche subsegments.
We look at the recent initial public offerings by Carlsmed and Shoulder Innovations, the first orthopedic IPOs in a number of years.
August 15, 2025
,
Mike Evers
A look at the current state of the foot and ankle market, the growth of core trauma and ways that smaller players are leveraging niche subsegments.
August 28, 2025
,
We look at the recent initial public offerings by Carlsmed and Shoulder Innovations, the first orthopedic IPOs in a number of years.
August 22, 2025
,
Under the agreement, Partners Group will acquire a significant minority stake in restor3d and provide $65 million of new equity.
August 22, 2025
,
The funding will accelerate ODI’s development of a fully integrated imaging platform for orthopedic surgery.
August 21, 2025
,
The company’s spine business grew in the mid-single-digits and extended its lead in placing enabling technology systems.
August 21, 2025
,
The company’s orthopedic sales declined in the high-single digits in the second quarter of 2025, but saw strong growth in regenerative.
August 15, 2025
,
Our chart of the month tracks Zimmer Biomet’s U.S. knee replacement and hip replacement sales over the last decade.
August 14, 2025
,
The company grew in the mid-single digits in the second quarter of 2025 and now has a full arsenal of bunion treatment systems.
August 14, 2025
,
The company drove high-single-digit growth in the second quarter of 2025 and plans to focus more on enabling technology innovation.
August 13, 2025
,
Excluding contributions from newly-acquired Nevro, Globus grew in the low single digits for the second quarter and first half of 2025.
August 12, 2025
,
The company grew in the high single digits in the second quarter of 2025, with a significant portion of growth coming from Paragon 28.
August 11, 2025
,
Stay up to date on the orthopedic market’s 2Q performance in 2025 as we update this post with company sales data and industry developments.
August 11, 2025
,
The company grew in the mid-single-digits amid steadily improving performance, operations and new product uptake.
August 8, 2025
,
The company grew in the low-single-digits as its completes a distributor transition but had notable wins in trauma and bone growth therapies.
August 7, 2025
,
Funds will support development of the company’s novel therapies for periprosthetic joint infection, a complication of joint replacement procedures.
